Rennova Health, Inc. announced that it has entered into a securities purchase agreement with certain existing institutional investors for a private placement of 4,400 shares of series O convertible redeemable preferred stock at a price of $909.090909 each share for gross proceeds of $4,000,000 on October 28, 2021. Each share of the series O preferred stock is convertible into shares of the company’s common stock. The company will receive the funding in two tranches of 2,200 shares each. The shares of series O preferred stock will be issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and by Rule 506 of Regulation D promulgated thereunder. The transaction is expected to close on or before December 1, 2021. The minimum investment accepted from any outside investor is $1. On the same date, the company issued 2,200 series O preferred stock for gross proceeds of $2,000,000 in its first tranche close.